Clinical toxicosis and erythrocyte cholinesterase inhibition of trichlorfon combined with mebendazole in horses.

This research article investigates the effects of varying doses of a combination antiparasitic medication, trichlorfon and mebendazole, on horses. The study found that this medication does not cause death even at high doses, but significant dosages lead to clinical signs of organophosphate toxicosis and inhibition of erythrocyte cholinesterase (ChE) activity.

Research Methodology and Participants

• The research involved thirty adult horses.
• Scientists administered differing doses of anthelmintic (anti-parasitic), comprised of trichlorfon and mebendazole.
• The administered dosage varied up to five times the effective dosage, which was 39.7 mg of trichlorfon and 8.8 mg of mebendazole for each kg of body weight.
• The research included control groups where horses received a placebo and were observed for side effects.

Key Findings

• Even high administered dosages didn’t result in deaths amongst the horses.
• Horses treated with recommended dosage amounts or placebo exhibited little to no side effects.
• Horses administered with higher dosages displayed an increase in the severity of clinical symptoms of organophosphate toxicosis in a dosage-dependent manner.
• A dosage-related suppression of erythrocyte cholinesterase (ChE) activity was also observed. ChE is an important enzyme for normal bodily functions and its inhibition may lead to issues related to neuromuscular function.
• Moreover, a second treatment at the recommended dosage given 35 days after the first treatment induced minimal or no side effects, despite the erythrocyte ChE activity remaining depressed before the repeat treatment.
• The research failed to detect any changes that would indicate organ toxicosis in any clinical pathologic determinations for any of the dosage groups. This suggests that the combination therapy might not cause overt organ damage.

Significance of the Study

• This research is crucial in understanding the potential harm or side effects that might be associated with the administration of the trichlorfon and mebendazole combination.
• It helps to provide dosage guidelines for the combination therapy to avoid instances of organophosphate toxicosis and enzyme inhibition.
• The study suggests that even if a higher dose is needed for effective treatment, it does not necessarily lead to death, though careful monitoring is required because of the possibility of increased side effects or toxicosis symptoms.
• It paves the way for further investigation into the effects of repeated treatments, especially considering the continued suppression of ChE activity.